
CLAIMS

1. Use of a compound represented by the following structural formula~~A method of treating a subject with acute myeloid leukemia or myelodysplastic syndrome, comprising administering an effective amount of Compound (I)~~:



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with acute myeloid leukemia or myelodysplastic syndrome, wherein:

the acute myeloid leukemia is relapsed or refractory.

2. The ~~method of~~use according to claim 1, wherein ~~Compound (I)~~the compound is a fumarate salt.

3. The ~~method of~~use according to claim 2, wherein the molar ratio between the compound~~Compound (I)~~ and fumaric acid is 1:1.

4. The use according to~~method of~~ any one of claims 1-3, wherein the subject has acute myeloid leukemia.

~~5. The method of claim 4, wherein the acute myeloid leukemia is relapsed or refractory.~~

~~6~~5. The use according to~~method of~~ any one of claims 1-~~4~~5, wherein the acute myeloid leukemia is complex karyotype acute myeloid leukemia.

~~7~~6. The use according to~~method of~~ any one of claims 1-5~~6~~, ~~further comprising co-administering~~ wherein an additional therapeutic agent is to be co-administered.

~~8~~7. The use according to~~method of~~ claim ~~7~~6, wherein the additional therapeutic agent is an anti-cancer drug.

~~9~~8. The use according to~~method of~~ claim ~~8~~7, wherein the anti-cancer drug is Venetoclax.


~~10~~9. The use according to~~method of~~ claim ~~8~~7, wherein the anti-cancer drug is 5-Azacytidine.

~~11~~10. The use according to~~method of~~ any one of claims ~~7-10~~6-9, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered concurrently.

~~12~~11. The use according to~~method of~~ any one of claims ~~7-10~~6-9, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered sequentially.

~~13~~12. The use according to~~method of~~ claim ~~8~~7, wherein the anti-cancer drug is decitabine.

~~14~~13. Use of a compound represented by the following structural formula~~A method of treating a subject with acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, comprising administering an effective amount of Compound (I)~~:



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma.

~~15~~14. The use according to~~method of~~ claim ~~14~~13, wherein the compound~~Compound (I)~~ is a fumarate salt.

~~16~~15. The use according to~~method of~~ claim ~~15~~14, wherein the molar ratio between the compound~~Compound (I)~~ and fumaric acid is 1:1.

~~17~~16. The use according to~~method of~~ any one of claims ~~14~~13-~~16~~15, wherein the subject has acute lymphoblastic leukemia.

~~18~~17. The use according to~~method of~~ claim ~~17~~16, wherein the acute lymphoblastic leukemia is T-cell acute lymphoblastic leukemia or B-cell acute lymphoblastic leukemia.

~~19~~18. The use according to ~~method of~~ any one of claims ~~14-16~~13-15, wherein the subject has chronic myeloid leukemia.

~~20~~19. The use according to~~method of~~ any one of claims ~~14-16~~13-15, wherein the subject has non-Hodgkin's lymphoma.

~~21~~20. The use according to~~method of~~ any one of claims ~~14-16~~13-15, wherein the subject has Burkitt lymphoma.

~~22~~21. The use according to~~method of~~ any one of claims ~~14-16~~13-15, wherein the subject has diffuse large B-cell lymphoma.

~~23~~22. The use according to~~method of~~ claim ~~22~~21, wherein the diffuse large B-cell lymphoma is germinal center B cell-like or activated B cell-like.

~~24~~23. The use according to~~method of~~ any one of claims ~~14-23~~13-22, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is relapsed or refractory.

~~25~~24. The use according to~~method of~~ any one of claims ~~14-24~~13-23, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is complex karyotype.

~~26~~25. The use according to~~method of~~ any one of claims ~~14-25~~13-24, ~~further comprising co-administering~~ wherein an additional therapeutic agent is to be co-administered.

~~27~~26. The use according to~~method of~~ claim ~~26~~25, wherein the additional therapeutic agent is an anti-cancer drug.

~~28~~27. The use according to~~method of~~ claim ~~27~~26, wherein the anti-cancer drug is Venetoclax, 5-Azacytidine, or decitabine.

~~29~~28. The use according to~~method of~~ any one of claims ~~26-28~~25-27, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are to be administered concurrently or sequentially.